Received by email:

File: Innovotech - Press Release Q3 2015 FINAL.PDF

                                            Press Release
                  Innovotech Reports Third Quarter 2015 Financial Results
Edmonton, Alberta, November 25, 2015   Innovotech Inc. (TSX-V: IOT), an innovator in the
field of biofilm product development, today announced its unaudited financial and operational
results for the quarter ended September 30, 2015.

Highlights

dot    Continued cost reductions initiated in 2014 led to a significant reduction in the losses
     incurred in the first three quarters of 2015 compared to those in the same quarters in 2014
dot    MBEC plate sales are almost double in the third quarter of this year compared to the same
     quarter in 2014
dot    11% of the contract research revenues in quarter are from a new clients

"Contract research revenues have not increased as desired, because of some client
cancelations and postponements, but we are especially pleased that 11% of the revenue in the
latest quarter comes from new clients." said General Manager Dr. Amin Omar. "Careful control
of costs and R&D expenditures has significantly reduced losses. Meanwhile an increase in plate
sales has affirmed the usefulness of the product and technology for those seeking to investigate
or validate antimicrobial claims."

Financial Summary

                       2015                                     2014                                  2013

    ($)      Q3         Q2         Q1         Q4         Q3            Q2          Q1          Q4             Q3
Gross
           185,513    183,804    175,216    371,638    135,913     193,747       201,322     175,242         175,396
revenue
R&D
           58,022     74,722     69,465      45,564     91,681         99,288    154,062     103,646         140,067
expense

Net
income     (47,135)   (92,988)   (60,409)   161,643   (132,993)   (108,865)     (129,425)   (275,133)    (206,636)
(loss)

Net
income
(loss)      (0.00)     (0.00)     (0.00)     0.01      (0.00)      (0.00)        (0.00)      (0.01)          (0.01)
per
share



Revenues

In the three month period ended September 30, 2015, total revenues were $185,513 (2014 -
$183,804). This included contract research revenue of $120,745 (2014 - $102,269) and product
sales of $64,768 (2014- $33,644). In the nine month period ended September 30, 2015, total
revenues were $544,533 (2014   $530,983).
 General and Administrative Expense

In the three month period ended September 30, 2015, general and administrative expense,
including stock based compensation expense and allocated amortization expense, was
$104,597 (2014 - $128,703). In the nine month period ended September 30, 2015, general and
administrative expenses were $344,383 (2014   $411,292). The reduction of expenses is a
result of various cost saving measures initiated during 2014, including staff reductions and
reduction of office rent.

Research and Development

In the three month period ended September 30, 2015, research and development expense,
including allocated amortization and patents costs, was $58,022 (2014   $91,681). The cost
was partially offset by various grants of $7,398 (2014   $32,917). In the nine month period
ended September 30, 2015, research and development expense was $202,209 (2014  
$345,030). The decrease in costs is mainly attributed to the freeze of agricultural programs in
favor of the development of the InnovoSIL product line.

Liquidity and Capital Resources

At September 30, 2015, the Company had $14,314 in cash compared to $4,795 at December
31, 2014.

Disciplined investment in development in the Company's lead products, an increase in revenues
during the fourth quarter 2014 and the increase in deferred revenues for future projects have
contributed to an increase in cash reserves.

At present, the Company's expenses are in excess of its revenue, thereby creating year to date
losses that have accumulated since the Company's inception. However, the loss for the nine
month period ended September 30, 2015 is 46% lower than that in 2014.

About Innovotech Inc.

For more information contact:

Dr. James Timourian, President                                Connect with us:
Innovotech Inc.                                               Website: www.innovotech.ca

Email: james.timourian@innovotech.ca
Telephone: 780,448.0585 ext 221
This document may contain forward-looking statements that are predictive in nature and subject to risks and
uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past res
--->ults
and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such
risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predict
--->ing
regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of
customers including government organizations; fluctuations in operating results; government policies or actions;
progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual pro
--->perty
protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters
beyond the control of management. Should known or unknown risks or uncertainties materialize, or should
management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The
Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by
applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.